Beta test rollout. This site is in community QA — please send feature requests, bug reports and data corrections on the Feedback page or on GitHub.

Home
    Disclaimer
    Clorazepate molecular structure

    Clorazepate Stats & Data

    Tranxene Tranzene Novo-clopate
    PubChem
    MW314.72
    FormulaC16H11ClN2O3
    LogP3.3
    IUPAC7-chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine-3-carboxylic acid
    InChIKeyXDDJGVMJFWAHJX-UHFFFAOYSA-N
    Chemical Class 1,4-Benzodiazepine
    Psychoactive Class Depressant

    Pharmacology

    DrugBank
    State Solid

    Description

    A water-soluble benzodiazepine derivative effective in the treatment of anxiety. It has also muscle relaxant and anticonvulsant actions.

    Mechanism of Action

    Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.

    Pharmacodynamics

    Clorazepate is a member of the group of drugs called benzodiazepines. Pharmacologically, clorazepate has the characteristics of the benzodiazepines. It has depressant effects on the central nervous system. The primary metabolite, nordiazepam, quickly appears in the blood stream. Studies in healthy men have shown that clorazenate has depressant effects on the central nervous system. Since orally administered clorazepate dipotassium is rapidly decarboxylated to form nordiazepam, there is essentially no circulating parent drug.

    Metabolism

    The drug is metabolized in the liver and excreted primarily in the urine. The primary metabolite, nordiazepam, is further metabolized by hydroxylation. The major urinary metabolite is conjugated oxazepam (3-hydroxynordiazepam), and smaller amounts of conjugated p-hydroxynordiazepam and nordiazepam are also found in the urine.

    Absorption

    Rapidly absorbed following oral administration (bioavailability is 91%).

    Indication

    For the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Also used as adjunctive therapy in the management of partial seizures and for the symptomatic relief of acute alcohol withdrawal.

    Half-life

    The serum half-life is about 2 days. Nordiazepam, the primary metabolite, quickly appears in the blood and is eliminated from the plasma with an apparent half-life of about 40 to 50 hours.

    Protein Binding

    The protein binding of nordiazepam in plasma is high (97-98%).

    Elimination

    The drug is metabolized in the liver and excreted primarily in the urine.

    Toxicity

    PubChem DrugBank

    Clorazepate dipotassium is classified as a psychloleptc, anxiolytic benzodiazepine derivative. White or light yellow solid crystals which are soluble in water, practically insoluble in acetone, in chloroform in dichloromethane and in ether. Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABA<sub>A</sub>) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor.

    LD50

    • LD50: 1320 mg/kg (Oral, Rat) (A308)
    • LD50: >1600 mg/kg (Oral, Rat)

    Carcinogenicity

    No indication of carcinogenicity to humans (not listed by IARC).

    Health effects (PubChem excerpts)

    May cause a potentially dangerous rash that may develop into Stevens Johnson syndrome, an extremely rare but potentially fatal skin disease.

    Effect Profile

    Curated
    Benzodiazepine 7.4

    Strong anxiolysis and euphoria with mild cognitive impairment, low sedation

    Anxiolysis×3
    10
    Sedation / Relaxation×2
    3
    Motor / Cognitive Impairment×1
    4
    Euphoria / Mood Lift×1
    10
    Based on reports from:

    Tolerance & Pharmacokinetics

    drugs.wiki

    No tolerance chart. Our decay curves for these drugs were estimates, and a curve can make tolerance look longer-lasting than it is, which is the dangerous direction.

    How fast tolerance to these drugs fades after a break has not been measured well enough to draw, so don't count on a dose you used to take still being safe: after time off, start with a much smaller amount and don't use alone. Mixing sedatives with each other, with alcohol or with opioids sharply raises the risk of a fatal overdose. If you've been using regularly, don't stop suddenly: withdrawal from benzodiazepines, alcohol or GHB/GBL can cause seizures or delirium, so get medical help to cut down gradually.

    Sources: FRANK: benzodiazepines · Alcohol and Drug Foundation: GHB · FDA 2020: benzodiazepine boxed warning · FDA 2019: gabapentinoids and breathing · NHS: alcohol use disorder

    Experience Report Analysis

    Erowid
    1 Reports
    0 Single-substance
    2007–2007 Date Range

    Demographics

    Gender Distribution

    Too few reports for a chart: gender is known from 1 report, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?

    • Male 1 of 1

    Reports Over Time

    Benzodiazepine Equivalence

    15.0 mg Clorazepate = 10.0 mg Diazepam
    Potency ratio 0.67
    Bioavailability Oral: 91%.

    Clorazepate - 15mg ~=10mg Diazepam.

    ⚠ All other CNS depressants.
    ← Back to Clorazepate